147 related articles for article (PubMed ID: 35548958)
1. EVALUATION OF 5-FLUOROURACIL-INDUCED CARDIOTOXICITY: ROLE OF CARDIAC BIOMARKERS.
Moghaddam Z; Rostami M; Zeraatchi A; Abadi H; Karamitanha F; Amirmoghaddami H
Exp Oncol; 2022 May; 44(1):60-66. PubMed ID: 35548958
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.
Peng J; Dong C; Wang C; Li W; Yu H; Zhang M; Zhao Q; Zhu B; Zhang J; Li W; Wang F; Wu Q; Zhou W; Yuan Y; Qiu M; Chen G
Cancer Commun (Lond); 2018 May; 38(1):22. PubMed ID: 29764506
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
[No Abstract] [Full Text] [Related]
4. Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
Upshaw JN; O'Neill A; Carver JR; Dimond EP; Denlinger CS; Kircher SM; Wagner LI; Ky B; Brell JM
Clin Colorectal Cancer; 2019 Mar; 18(1):44-51. PubMed ID: 30348619
[TBL] [Abstract][Full Text] [Related]
5. Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study.
Dyhl-Polk A; Schou M; Vistisen KK; Sillesen AS; Serup-Hansen E; Faber J; Klausen TW; Bojesen SE; Vaage-Nilsen M; Nielsen DL
Oncologist; 2021 Mar; 26(3):e403-e413. PubMed ID: 32959474
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer.
Schöber C; Papageorgiou E; Harstrick A; Bokemeyer C; Mügge A; Stahl M; Wilke H; Poliwoda H; Hiddemann W; Köhne-Wömpner CH
Cancer; 1993 Oct; 72(7):2242-7. PubMed ID: 8374883
[TBL] [Abstract][Full Text] [Related]
7. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frödin JE; Shah CH; Sorbye H; Ristamäki R; Halonen P; Soveri LM; Heervä E; Ålgars A; Bärlund M; Hagman H; McDermott R; O'Reilly M; Röckert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B
ESMO Open; 2022 Jun; 7(3):100427. PubMed ID: 35798468
[TBL] [Abstract][Full Text] [Related]
8. Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients.
Jin X; Bai Y; Gao L; Wu S
Cancer Chemother Pharmacol; 2019 Sep; 84(3):599-607. PubMed ID: 31203389
[TBL] [Abstract][Full Text] [Related]
9. Fluoropyrimidine-associated cardiotoxicity: revisited.
Saif MW; Shah MM; Shah AR
Expert Opin Drug Saf; 2009 Mar; 8(2):191-202. PubMed ID: 19309247
[TBL] [Abstract][Full Text] [Related]
10. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Kelly C; Bhuva N; Harrison M; Buckley A; Saunders M
Eur J Cancer; 2013 Jul; 49(10):2303-10. PubMed ID: 23583220
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up.
Meydan N; Kundak I; Yavuzsen T; Oztop I; Barutca S; Yilmaz U; Alakavuklar MN
Jpn J Clin Oncol; 2005 May; 35(5):265-70. PubMed ID: 15855175
[TBL] [Abstract][Full Text] [Related]
12. Symptomatic cardiotoxicity associated with 5-fluorouracil.
Meyer CC; Calis KA; Burke LB; Walawander CA; Grasela TH
Pharmacotherapy; 1997; 17(4):729-36. PubMed ID: 9250550
[TBL] [Abstract][Full Text] [Related]
13. 5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Mar; 18(1):58-63. PubMed ID: 30470591
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center.
Khan MA; Masood N; Husain N; Ahmad B; Aziz T; Naeem A
J Pak Med Assoc; 2012 May; 62(5):430-4. PubMed ID: 22755303
[TBL] [Abstract][Full Text] [Related]
15. 5-Fluorouracil Rechallenge After Cardiotoxicity.
Desai A; Mohammed T; Patel KN; Almnajam M; Kim AS
Am J Case Rep; 2020 Aug; 21():e924446. PubMed ID: 32860674
[TBL] [Abstract][Full Text] [Related]
16. Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients.
Seker M; Isen HC; Çevirme N; Aydın S; Bilici A; Bulut H; Yasin AI; Coban E; Demir T; Aliyev A; Kocyigit A; Turk HM
Oncol Res Treat; 2018; 41(9):545-549. PubMed ID: 30121640
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
Tsavaris N; Kosmas C; Vadiaka M; Efremidis M; Zinelis A; Beldecos D; Sakelariou D; Koufos C; Stamatelos G
Med Sci Monit; 2002 Jun; 8(6):PI51-7. PubMed ID: 12070449
[TBL] [Abstract][Full Text] [Related]
18. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study.
Akhtar SS; Salim KP; Bano ZA
Oncology; 1993; 50(6):441-4. PubMed ID: 8233284
[TBL] [Abstract][Full Text] [Related]
19. 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity.
Jensen SA; Sørensen JB
Cancer Chemother Pharmacol; 2012 Jan; 69(1):57-64. PubMed ID: 21603868
[TBL] [Abstract][Full Text] [Related]
20. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.
Saif MW; Garcon MC; Rodriguez G; Rodriguez T
In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
